Industry Odisha Bureau, Sep 20: ENTOD Pharmaceuticals has secured a patent for topical insulin eye drops. The programme remains in pre-clinical development. Safety, efficacy and potential clinical applications still need further research.
ENTOD Pharmaceuticals has secured a patent for its topical insulin eye drops. The Mumbai-based company says the product remains at the pre-clinical stage. Clinical safety and efficacy have not yet been established. The patent marks an intellectual-property milestone, not a medical one.
ENTOD Insulin Eye Drops Remain Pre-Clinical
ENTOD says the insulin eye drops are under investigation. It describes them as a potential novel therapeutic approach. The company links the work to unmet needs in ophthalmic care. Pre-clinical research precedes any study in patients.
A patent is different from drug approval. It establishes intellectual-property rights. It does not show that a medicine works. Nor does it clear a product for patients. The announcement mentions no launch date, regulatory filing or price.
Why Researchers Are Studying Insulin for Eye Care
Insulin is best known as a diabetes treatment. Its biological role has drawn scientific interest beyond blood-sugar management. ENTOD is exploring insulin through an ophthalmic delivery route. That means studying an established biological molecule in a different way.
A new delivery route can open research opportunities. It does not automatically improve outcomes. The announcement names no specific eye condition.
Safety and Efficacy Still Need Clinical Evidence
Safety remains to be established. Therapeutic efficacy remains to be established. Potential clinical applications also remain uncertain. ENTOD says further pre-clinical and clinical research will be required.
Pre-clinical programmes remain research-stage projects. The announcement does not describe any human trials. The patent should not be read as treatment approval.
ENTOD Links Patent to Indian Pharmaceutical Research
ENTOD frames the patent within India’s pharmaceutical research ambitions. It says the industry is moving beyond generics. It cites original research, intellectual-property creation and novel drug development.
Nikkhil K Masurkar is chief executive of ENTOD Pharmaceuticals. He called the patent a scientific achievement. He also described it as a sign of India’s growing capacity for original innovation.
He said the work is for India, the Global South and, ultimately, the world. These are company statements. They are not independent scientific validation. One patent does not transform a sector.
Ophthalmology Expert Stresses Further Research
Dr B Vijaya Lakshmi is an Associate Professor at Sarojini Devi Eye Hospital in Hyderabad. She specialises in cornea, cataract and refractive surgery.
She said insulin is familiar mainly as a diabetes treatment. Its biological role, she said, interests scientists well beyond blood-sugar management. She called ophthalmic delivery an innovative and fascinating research direction.
She said studying an established molecule through another route could potentially yield new understanding. Her caution was equally clear. Safety and therapeutic value need “rigorous research and clinical studies.”
Patent Marks Early Step, Not Clinical Approval
The ENTOD patent is an early step. It shows intellectual-property progress. It does not answer the larger medical question.
Whether insulin eye drops are safe remains unknown. Whether they work also remains unknown. Further pre-clinical and clinical research must decide that. The focus now shifts from intellectual property to medical validation.
